GlassScriptPhysician profile
James P Cho
NPI 1376706754
$118,241.53
in general payments reported to CMS, 2019-2025
35 companies · $35K in 2025
The $35K reported for 2025 was more than what 97% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,097 · 2020: $318 · 2021: $2,099 · 2022: $2,840 · 2023: $50K · 2024: $26K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Honoraria: $24K · Food and Beverage: $15K · Travel and Lodging: $6,743 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,175.00 |
| Honoraria | $24,350.00 |
| Food and Beverage | $15,479.89 |
| Travel and Lodging | $6,743.04 |
| Education | $140.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $63,702.36 | 2021-2025 | Vraylar |
| Supernus Pharmaceuticals, INC. | $37,302.33 | 2022-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,407.16 | 2021-2025 | Caplyta |
| Corium, LLC | $1,833.47 | 2021-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $1,767.44 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $1,567.92 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $1,399.10 | 2022-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $1,209.89 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $989.09 | 2019-2025 | Spravato, Invega Sustenna |
| Lundbeck LLC | $716.15 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $712.30 | 2019-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $657.81 | 2021-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $612.73 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $494.21 | 2019-2025 | Fanapt |
| Idorsia Pharmaceuticals US INC | $446.93 | 2022-2025 | Quviviq, Quviviq |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $276.24 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $266.66 | 2019-2023 | Nuplazid |
| Noven Therapeutics, LLC | $256.78 | 2021-2025 | Xelstrym, Secuado |
| Allergan, INC. | $216.29 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $211.35 | 2019-2023 | Belsomra |
| Collegium Pharmaceutical, INC. | $179.98 | 2025 | Jornay Pm |
| Tris Pharma INC | $168.28 | 2023-2025 | Dyanavel Xr |
| Bausch Health US, LLC | $143.89 | 2021-2024 | Aplenzin |
| Orexo US, INC. | $119.01 | 2021 | |
| Braeburn INC. | $112.50 | 2025 | Brixadi |
| Ironshore Pharmaceuticals INC. | $110.82 | 2022-2024 | Jornay Pm |
| Indivior INC. | $74.31 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $70.19 | 2019-2022 | |
| Almatica Pharma LLC | $65.90 | 2021-2023 | Loreev Xr |
| Adlon Therapeutics L.P. | $45.26 | 2019-2021 | |
| Vertical Pharmaceuticals, LLC | $36.26 | 2025 | Relexxii |
| Tempus Ai, INC | $23.66 | 2024 | |
| Janssen Scientific Affairs, LLC | $20.46 | 2025 | Invega Sustenna, Spravato |
| Tms Neurohealth Centers INC. | $13.79 | 2025 | Tms Neurohealth Centers INC. |
| Mdd US Operations, LLC | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.